Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17171332 | 1.00 | FFAR3 (0.37) | FFAR3CYP2C19TSHRNFKB1MEN1 | |
| Hydrochloric Acid SCHEMBL27092759 | 0.98 | FFAR3 (0.36) | FFAR3CYP2C19TSHRNFKB1KMT2A | |
| SCHEMBL369709 | 0.93 | FFAR3 (0.39) | FFAR3CYP2C19TSHRNFKB1 | |
| SCHEMBL2275708 | 0.93 | FFAR3 (0.39) | FFAR3CYP2C19TSHRNFKB1 | |
| SCHEMBL359077 | 0.93 | FFAR3 (0.39) | FFAR3CYP2C19TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL19022236 | 0.91 | FFAR3 (0.37) | FFAR3CYP2C19TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL19022235 | 0.91 | FFAR3 (0.37) | FFAR3CYP2C19TSHRNFKB1 | |
| SCHEMBL28616020 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL11303377 | 0.82 | FFAR3 (0.40) | FFAR3CYP2C19TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL11303374 | 0.82 | FFAR3 (0.40) | FFAR3CYP2C19TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022070287-A1 | MACROCYCLE COMPOUND | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10159745-B2 | Tubulysin derivatives | MEDIMMUNE, LLC (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180362519-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2018-12-20 | — | — | US | disclosed |
| WO-2017134547-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| EP-3129362-A1 | TUBULYSIN DERIVATIVES | Medimmune, LLC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9427479-B2 | Tubulysin derivatives | MEDIMMUNE LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2015157594-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10159745-B2 | Tubulysin derivatives | TEKT1, TWF2, TEK | FFAR3 4179/4885CYP2C19 4820/4885TSHR 3572/4885 |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | FFAR3 4179/4885CYP2C19 4820/4885TSHR 3572/4885 |
| US-20180362519-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | NGLY1, TEK, TEKT1 | FFAR3 2962/4885CYP2C19 4730/4885TSHR 2105/4885 |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | FFAR3 4179/4885CYP2C19 4820/4885TSHR 3572/4885 |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | FFAR3 2962/4885CYP2C19 4730/4885TSHR 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.